Chief Executive Officer
Alex Haahr Gouliaev
Alex Haahr Gouliaev, Chief Executive Officer, holds an MSc and PhD in Chemistry from Aarhus University, Denmark. During his education, he studied at University of Southern Denmark, Odense; Dept. of Pharmacology, Odense University Hospital; Dept. of Chemistry, Aarhus University and Dept. of Medicinal Chemistry, The Royal School of Pharmacy, Copenhagen University.
Alex is a co-founder of Nuevolution. He served as Executive Vice President, Chemistry and Drug Discovery from 2001 until he was appointed Chief Executive Officer in September 2005. At Nuevolution, he has been considerably involved in the establishing of Nuevolution’s platform technology for drug discovery from conception to realization. Furthermore, he has been significantly involved in Nuevolution’s partnered and internal drug discovery programs. During the period 2005-2015, he has been responsible for the negotiation and execution of 14 out of the company’s 15 agreements based on Nuevolution’s drug discovery platform.
Prior to co-founding Nuevolution, he was Director of Medicinal Chemistry, member of the Management group, and a member of the Board of Directors at NeuroSearch A/S, where he worked for 6 years. During his stay at Neurosearch, he was involved in multiple CNS projects as project manager including responsibility for projects ranging from early discovery to out-sourcing and technology transfer to CRO’s for GMP production of API’s for clinical study use.
During his 20 years of industry practice, he has gained experience and expertise in medicinal chemistry, pharmacology, process chemistry optimization and up-scaling of clinical candidates, technology platform development, patenting, contract drafting and negotiation, and capital raising. Alex has authored or co-authored more than 40 publications and patent applications in the fields of synthetic/medicinal chemistry, CNS pharmacology and technology development.
Number of shares: 70,778
Number of warrants: 1,911,113 warrants series 2